What is MET in Lung Cancer? – Lung Cancer Europe
Lung Cancer Europe shared a post on LinkedIn:
“What is MET in lung cancer?
MET is a gene that helps cells grow and repair.
When it changes, it can drive cancer.
Some people have MET changes from the start, like exon 14 skipping or amplification.
Others develop MET alterations after treatment, for example, after EGFR-targeted therapy stops working.
These changes are more common in non-squamous NSCLC but can affect other lung cancer types too.
MET changes are found in:
- Around 3–4% of NSCLC cases
- Up to 30% of people with resistance to EGFR treatment
There are now targeted drugs available that can treat MET-driven cancers.
More treatments are in development.
Ask your team whether MET was included in your biomarker testing even if it wasn’t tested the first time.
It could help guide future treatment options.”
More posts featuring Lung Cancer Europe.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023